Advertisement

Organisation › Details
Valneva (Group)
Valneva is a biotech company developing and commercializing vaccines for infectious diseases with major unmet needs. Valneva’s portfolio includes two commercial vaccines for travelers: IXIARO®/JESPECT® indicated for the prevention of Japanese encephalitis and DUKORAL® indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by ETEC. The Company has various clinical-stage vaccines in development including unique vaccines against Lyme disease and chikungunya. Valneva has operations in Austria, Sweden, the United Kingdom, France, Canada and the US with approximately 490 employees. *
![]() |
Start | 2013-05-28 merged |
Predecessor | Vivalis (Group) | |
![]() |
Industry | avian (bird) production technology (transgenic) |
Industry 2 | vaccine | |
![]() |
Person | Lingelbach, Thomas (Intercell 201106– CEO before COO before 2001– Chiron Behring) |
Person 2 | Grimaud, Franck (Vivalis 200702 CEO) | |
![]() |
Region | Lyon |
Country | France | |
Street | 6 rue Alain Bombard Campus Bio-Quest | |
City | 44800 Saint-Herblain | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | E: 501 to 1,000 (2021-09-30) |
Currency | EUR | |
Annual sales | 110,321,000 (revenues, total, consolidated (2020) 2020-12-31) | |
Profit | -64,393,000 (2020-12-31) | |
Cash | 329,766,000 (2021-06-30) | |
* Document for �About Section�: Valneva S.E.. (1/9/20). "Press Release: Valneva Expands its Commercial Operations with the Opening of its French Commercial Office". Saint-Herblain. | ||
Record changed: 2021-10-30 |
Advertisement
![Picture [iito] No Tracking 650x100px](/banner/iito-business-intelligence-20211013-650-100-summer-banner-series-no-tracking.jpg)
More documents for Valneva (Group)
- [1] Valneva S.E.. (4/25/22). "Press Release: Valneva Provides Regulatory Update on its inactivated COVID-19 Vaccine Candidate". Saint-Herblain....
- [2] Valneva S.E.. (2/21/22). "Press Release: Valneva Awarded Up to £20 Million by Scottish Enterprise to Advance Vaccine Development". Saint-Herblain....
- [3] Valneva S.E.. (11/23/21). "Press Release: Valneva Signs Purchase Agreement with European Commission for its Inactivated COVID-19 Vaccine VLA2001". Saint-Herblain....
- [4] Valneva S.E.. (11/10/21). "Press Release: Valneva Announces European Commission Approval of Advance Purchase Agreement for up to 60 Million Doses of Inactivated COVID-19 Vaccine VLA2001". Saint-Herblain....
- [5] Valneva S.E.. (11/8/21). "Press Release: Valneva to Present and Hold Investor Meetings at the Jefferies London Healthcare Conference". Saint-Herblain....
- [6] Valneva S.E.. (10/29/21). "Press Release: Valneva Announces the Pricing of its Global Offering of American Depositary Shares and Ordinary Shares". Saint-Herblain....
- [7] Valneva S.E.. (10/26/21). "Press Release: Valneva Announces Launch of Proposed Global Offering of American Depository Shares and Ordinary Shares". Saint-Herblain....
- [8] Valneva S.E.. (10/18/21). "Press Release: Valneva Reports Positive Phase 3 Results for Inactivated, Adjuvanted COVID-19 Vaccine Candidate VLA2001". Saint-Herblain....
- [9] Valneva S.E.. (9/13/21). "Press Release: Valneva Receives Notice of Termination of COVID-19 Vaccine Supply Agreement by UK Government". Saint-Herblain....
- [10] Valneva S.E.. (9/3/21). "Press Release: Valneva – U.S. DoD Exercises First Year Option on Ixiaro Supply Contract". Saint-Herblain....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top